Syngene International announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early‑stage drug discovery programs and platform technologies emerging from the university’s research labs.
The collaboration will be delivered by Syngene SynVent™, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development. Syngene’s Connector model, which is designed to bridge high-potential, early-stage assets and technology platforms with strategic investors and downstream partnerships will be leveraged to bring together relevant stakeholders to sponsor research and secure licensing options for the resulting intellectual property.